Sravanti Therapy: Emerging Frontier in EGFR-Mutant and MET-Positive Advanced NSCLC

The key evaluation endpoint of this Phase II, single-arm study on the efficacy and safety of sravanti in EGFR-mutant and MET-overexpressing and/or MET-amplified locally advanced or metastatic NSCLC patients progressing after osimertinib treatment was the investigator-assessed ORR. This study is considered one of the core global studies for sravanti, as osimertinib has demonstrated remarkable performance in the global market, with sales reaching $5.799 billion (+7%) in 2023. Facing such immense market potential, AstraZeneca is strategically positioning sravanti in combination with osimertinib to further solidify its market position.

AstraZeneca's 2023 financial report highlights the success of the FLAURA2 study, which has demonstrated the advantages of osimertinib plus chemotherapy in the first-line treatment of EGFR-mutant NSCLC. Additionally, the Phase II registrational SAVANNAH study and the Phase III SAFFRON study for second-line EGFR-mutant NSCLC are actively in preparation, indicating AstraZeneca's ongoing investment and strategy in this field.

While Johnson & Johnson's Rybrevant (amivantamab) has shown some competitiveness in the EGFR-mutant advanced NSCLC post-osimertinib setting, the sravanti plus osimertinib combination strategy has displayed significant advantages in terms of efficacy, safety, and patient compliance. Preliminary data from the SAVANNAH study suggest that for patients with MET IHC ≥90% or FISH ≥10 after osimertinib resistance, the ORR reached 52% with a median progression-free survival of 7.2 months when treated with the sravanti plus osimertinib combination.

On the other hand, Dizal Pharmaceutical's sulfovanti has emerged as a promising option for EGFR ex20ins-mutant NSCLC. Following its approval and launch in China in August 2023, sulfovanti's global market expansion strategy has become a focal point. Through the international clinical registration study "Wu-Kong1B," sulfovanti has demonstrated remarkable efficacy in the treatment of locally advanced or metastatic NSCLC with EGFR ex20ins mutations, with an ORR of 53.3%, bringing a new therapeutic option to this field.

Global expansion is a crucial strategic direction for the innovative drug sector. Beigene's zebutinib, as the first domestically-developed innovative drug approved in the US, has garnered significant market attention. Looking ahead, Hutchison MediPharma's sravanti and Dizal Pharmaceutical's sulfovanti are expected to submit new drug applications (NDAs) in the US, and their global commercialization performance is eagerly anticipated.